Literature DB >> 28929345

Pemafibrate: First Global Approval.

Hannah A Blair1.   

Abstract

Pemafibrate (Parmodia®) is a novel, highly selective peroxisome proliferator-activated receptor (PPAR)-α modulator (SPPARM). It acts by binding to PPAR-α and regulating the expression of target genes that modulate lipid metabolism, thereby decreasing plasma triglyceride levels and increasing high-density lipoprotein cholesterol levels. Developed by Kowa Company, Ltd., oral pemafibrate has been approved in Japan for the treatment of hyperlipidaemia (including familial hyperlipidaemia). This article summarizes the milestones in the development of pemafibrate leading to this first global approval for hyperlipidaemia.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28929345     DOI： 10.1007/s40265-017-0818-x

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  7 in total

1.  The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis.

Authors:  Nathalie Hennuyer; Isabelle Duplan; Charlotte Paquet; Jonathan Vanhoutte; Eloise Woitrain; Véronique Touche; Sophie Colin; Emmanuelle Vallez; Sophie Lestavel; Philippe Lefebvre; Bart Staels
Journal:  Atherosclerosis       Date:  2016-03-04       Impact factor: 5.162

2.  Transcriptome Analysis of K-877 (a Novel Selective PPARα Modulator (SPPARMα))-Regulated Genes in Primary Human Hepatocytes and the Mouse Liver.

Authors:  Sana Raza-Iqbal; Toshiya Tanaka; Motonobu Anai; Takeshi Inagaki; Yoshihiro Matsumura; Kaori Ikeda; Akashi Taguchi; Frank J Gonzalez; Juro Sakai; Tatsuhiko Kodama
Journal:  J Atheroscler Thromb       Date:  2015-06-04       Impact factor: 4.928

3.  Effects of K-877, a novel selective PPARα modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice.

Authors:  Kenta Takei; Yoshimi Nakagawa; Yunong Wang; Song-Iee Han; Aoi Satoh; Motohiro Sekiya; Takashi Matsuzaka; Hitoshi Shimano
Journal:  J Pharmacol Sci       Date:  2017-02-11       Impact factor: 3.337

4.  Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia.

Authors:  Hidenori Arai; Shizuya Yamashita; Koutaro Yokote; Eiichi Araki; Hideki Suganami; Shun Ishibashi
Journal:  Atherosclerosis       Date:  2017-03-24       Impact factor: 5.162

5.  Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial.

Authors:  Shun Ishibashi; Shizuya Yamashita; Hidenori Arai; Eiichi Araki; Koutaro Yokote; Hideki Suganami; Jean-Charles Fruchart; Tatsuhiko Kodama
Journal:  Atherosclerosis       Date:  2016-02-26       Impact factor: 5.162

6.  Selective peroxisome proliferator-activated receptor-α modulator K-877 efficiently activates the peroxisome proliferator-activated receptor-α pathway and improves lipid metabolism in mice.

Authors:  Kenta Takei; Song-Iee Han; Yuki Murayama; Aoi Satoh; Fusaka Oikawa; Hiroshi Ohno; Yoshinori Osaki; Takashi Matsuzaka; Motohiro Sekiya; Hitoshi Iwasaki; Shigeru Yatoh; Naoya Yahagi; Hiroaki Suzuki; Nobuhiro Yamada; Yoshimi Nakagawa; Hitoshi Shimano
Journal:  J Diabetes Investig       Date:  2017-04-25       Impact factor: 4.232

7.  A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice.

Authors:  Masami Sairyo; Takuya Kobayashi; Daisaku Masuda; Koutaro Kanno; Yinghong Zhu; Takeshi Okada; Masahiro Koseki; Tohru Ohama; Makoto Nishida; Yasushi Sakata; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2017-08-05       Impact factor: 4.928
  7 in total
  10 in total

Review 1.  PPAR Agonists and Metabolic Syndrome: An Established Role?

Authors:  Margherita Botta; Matteo Audano; Amirhossein Sahebkar; Cesare R Sirtori; Nico Mitro; Massimiliano Ruscica
Journal:  Int J Mol Sci       Date:  2018-04-14       Impact factor: 5.923

2.  Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial.

Authors:  Hidenori Arai; Shizuya Yamashita; Koutaro Yokote; Eiichi Araki; Hideki Suganami; Shun Ishibashi
Journal:  J Atheroscler Thromb       Date:  2018-04-07       Impact factor: 4.928

3.  Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment.

Authors:  Koutaro Yokote; Shizuya Yamashita; Hidenori Arai; Eiichi Araki; Hideki Suganami; Shun Ishibashi; On Behalf Of The K-Study Group
Journal:  Int J Mol Sci       Date:  2019-02-06       Impact factor: 5.923

4.  Comparative efficacy of pharmacological agents on reducing the risk of major adverse cardiovascular events in the hypertriglyceridemia population: a network meta-analysis.

Authors:  Yan-Yan Qi; Li Yan; Zhong-Min Wang; Xi Wang; Hua Meng; Wen-Bo Li; Dong-Chang Chen; Meng Li; Jun Liu; Song-Tao An
Journal:  Diabetol Metab Syndr       Date:  2021-01-29       Impact factor: 3.320

Review 5.  Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?

Authors:  Jean-Charles Fruchart; Michel P Hermans; Jamila Fruchart-Najib; Tatsuhiko Kodama
Journal:  Curr Atheroscler Rep       Date:  2021-01-03       Impact factor: 5.113

Review 6.  PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients.

Authors:  Naomi F Lange; Vanessa Graf; Cyrielle Caussy; Jean-François Dufour
Journal:  Int J Mol Sci       Date:  2022-04-13       Impact factor: 6.208

7.  Clinically Relevant Dose of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα), Lowers Serum Triglyceride Levels by Targeting Hepatic PPARα in Mice.

Authors:  Zhe Zhang; Pan Diao; Xuguang Zhang; Takero Nakajima; Takefumi Kimura; Naoki Tanaka
Journal:  Biomedicines       Date:  2022-07-11

Review 8.  Hypertriglyceridemia: new approaches in management and treatment.

Authors:  Anna Wolska; Zhi-Hong Yang; Alan T Remaley
Journal:  Curr Opin Lipidol       Date:  2020-12       Impact factor: 4.616

Review 9.  Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.

Authors:  Shizuya Yamashita; Daisaku Masuda; Yuji Matsuzawa
Journal:  Curr Atheroscler Rep       Date:  2020-01-23       Impact factor: 5.113

Review 10.  Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH.

Authors:  Ryan D Welch; Cyrielle Billon; McKenna Losby; Gonzalo Bedia-Diaz; Yuanying Fang; Amer Avdagic; Bahaa Elgendy; Thomas P Burris; Kristine Griffett
Journal:  Metabolites       Date:  2022-03-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.